[HTML][HTML] Risk assessment and clinical implications of COVID-19 in multiple myeloma patients: A systematic review and meta-analysis
Introduction Patients with multiple myeloma (MM) face heightened infection susceptibility,
particularly severe risks from COVID-19. This study, the first systematic review in its domain …
particularly severe risks from COVID-19. This study, the first systematic review in its domain …
Endothelial injury and dysfunction with emerging immunotherapies in multiple myeloma, the impact of COVID-19, and endothelial protection with a focus on the …
CC Mo, E Richardson, E Calabretta, F Corrado… - Blood Reviews, 2024 - Elsevier
Patients with multiple myeloma (MM) were among the groups impacted more severely by the
COVID-19 pandemic, with higher rates of severe disease and COVID-19-related mortality …
COVID-19 pandemic, with higher rates of severe disease and COVID-19-related mortality …
[HTML][HTML] Impaired SARS-CoV-2-Specific CD8+ T Cells After Infection or Vaccination but Robust Hybrid T Cell Immunity in Patients with Multiple Myeloma
K Shoumariyeh, B Csernalabics, E Salimi Alizei… - Vaccines, 2024 - mdpi.com
Background: Multiple myeloma (MM) patients are at high risk of severe infections including
COVID-19 due to an immune dysregulation affecting both innate and adaptive immune …
COVID-19 due to an immune dysregulation affecting both innate and adaptive immune …
[HTML][HTML] Impact of SARS-CoV-2 on Viral Respiratory Infections in Patients with Hematological Malignancies
A Giordano, M Quattrone, M Viscovo, B Fiori… - Viruses, 2024 - mdpi.com
Patients with hematological malignancies (HMs) are at high risk of respiratory viral infections
due to the intrinsic deterioration of the immune system and chemotherapy treatments. In the …
due to the intrinsic deterioration of the immune system and chemotherapy treatments. In the …
Risk of SARS-CoV-2 infection and severe COVID-19 in hematological patients who received or not pre-exposure prophylaxis with tixagevimab/cilgavimab: a target …
M Falcone, G Tiseo, G Marchetti, J Kalo… - Leukemia & …, 2024 - Taylor & Francis
We emulated a hypothetical target trial in which hematological subjects cared at the
University Hospital of Pisa (Italy) received or not SARS-CoV-2 prophylaxis with tixagevimab …
University Hospital of Pisa (Italy) received or not SARS-CoV-2 prophylaxis with tixagevimab …
When Chinese patients with plasma cell disorders encountered the nationwide Omicron outbreak (December 2022): a real-world multicenter and multiregional study
X Jiang, X Han, F Jin, G An, J Hou, J He, Q Wang… - …, 2024 - Taylor & Francis
Objectives This study aims to assess the impact of the nationwide Omicron outbreak in
December 2022 on Chinese patients with plasma cell disorders (PCD), focusing on the …
December 2022 on Chinese patients with plasma cell disorders (PCD), focusing on the …
[HTML][HTML] Antibody response to breakthrough SARS-CoV-2 infection in “booster” vaccinated patients with multiple myeloma according to B/T/NK lymphocyte absolute …
N Sgherza, A Mestice, AMV Larocca… - … Journal of Hematology …, 2024 - ncbi.nlm.nih.gov
Lymphopenia (particularly low CD19+ B-lymphocyte count) and current treatment with either
anti-CD38 or anti-BCMA monoclonal antibodies (MoAbs) have been reported to significantly …
anti-CD38 or anti-BCMA monoclonal antibodies (MoAbs) have been reported to significantly …